PGEN Stock Analysis: Buy, Sell, or Hold?
PGEN - Precigen, Inc. Common Stock
$3.94
0.00 (0.13%)
▲
5d:
+1.16%
30d:
+10.85%
90d:
-5.86%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 13, 2026
Smart Money Accumulation
PGEN is down 3.0% this week, but smart money is accumulating calls. Top strike: $4 2026-04-17 with 1,605 OI. Call ratio: 99% View Scanner →
Strength: 6.4/10
Get Alerted When PGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PGEN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PGEN shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PGEN is currently trading at $3.94, which is considered extended relative to its 30-day fair value range of $3.27 to $3.80.
Technical Outlook: Technically, PGEN is in a strong uptrend. Immediate support is located at $3.04, while resistance sits at $4.28.
Market Sentiment: PGEN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.25 (+109.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PGEN is in a strong uptrend. Immediate support is located at $3.04, while resistance sits at $4.28.
Market Sentiment: PGEN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.25 (+109.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$3.27 -
$3.80
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 109.9% below Wall St target ($8.25)
Fair Price Analysis
30-Day Fair Range
$3.27 -
$3.80
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$3.04
Resistance Level
$4.28
Current Trend
Strong Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-27.33
Wall Street Target
$8.25
(+109.9%)
Revenue Growth (YoY)
19.4%
Share & Embed Analysis
Last updated: April 02, 2026 11:38 AM ET
Data refreshes hourly during market hours. Next update: 12:38 PM
Data refreshes hourly during market hours. Next update: 12:38 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Randal J Kirk
SELL
1900036 shares
2025-12-22
Randal J Kirk
SELL
937308 shares
2025-11-21
Randal J Kirk
SELL
942832 shares
2025-11-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 52 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 52 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$33 | 61 BUY |
Advanced PGEN Option Strategies
Professional options setups generated by AI based on today's PGEN price and gamma walls.
